<DOC>
	<DOCNO>NCT00004179</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . It yet know whether chemotherapy effective without rituximab relapse non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study combination chemotherapy rituximab see well work compare combination chemotherapy alone treat patient relapse non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Rituximab Treating Patients With Relapsed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate quality remission patient relapse follicular non-Hodgkin 's lymphoma treat cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) without rituximab . - Compare event-free survival overall survival patient treat regimen . - Determine effect rituximab maintenance therapy progression-free survival patient . OUTLINE : This randomize , multicenter study . - Induction : Patients randomize one two treatment arm . Patients stratify accord participate center , prior treatment purine analogue , age , number prior induction treatment best response obtain ( complete vs partial remission v change/progressive disease ) , time since diagnosis ( less 2 year vs 2 year ) , bulky disease ( le 10 cm v great 10 cm ) . - Arm I ( close 12/20/04 ) : Patients receive induction chemotherapy comprise cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 oral prednisone day 1-5 ( CHOP chemotherapy ) . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive CHOP chemotherapy arm I. Rituximab IV administer 1 hour prednisone IV drug . - Maintenance : Patients achieve partial complete remission randomize one two treatment arm . Patients stratify accord rituximab administration induction ( yes v ) , quality response ( complete vs partial remission v change/progressive disease ) , participate center . - Arm I : Patients receive therapy . - Arm II : Beginning 8 week last CHOP course , patient receive rituximab IV every 3 month 2 year absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 4 month thereafter . PROJECTED ACCRUAL : A total 752 patient accrue study within 6 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven stage III IV follicular nonHodgkin 's lymphoma ( NHL ) Relapsed response ( change/progressive disease ) 2 adequate nonanthracyclinecontaining systemic chemotherapy regimen At least 2 month singleagent therapy ( e.g. , chlorambucil ) AND/OR At least 2 consecutive course polychemotherapy ( e.g. , cyclophosphamide , vincristine , prednisone ) purine analogues Complete partial remission change least 4 week completion prior therapy OR progression one maximum 2 prior therapy regimens CD20 positive At least 1 bidimensionally measurable mass No great 10,000,000/mL circulate tumor cell IgG level least 3 g/L No lowgrade NHL transform intermediate highgrade NHL No symptomatic CNS lymphoma No bone marrow involvement NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2.5 time upper limit normal ( ULN ) Alkaline phosphatase less 2.5 time ULN Renal : Creatinine le 2.5 time ULN BUN less 2.5 time ULN Cardiovascular : No severe cardiac disease ( i.e. , severe heart failure require symptomatic treatment ) Pulmonary : No severe pulmonary disease Other : No severe neurologic psychiatric disease No severe metabolic disease Not pregnant Fertile patient must use effective contraception No prior malignancy within past 5 year except nonmelanomatous skin cancer , carcinoma situ cervix , cancer curatively treat surgical therapy HIV negative No uncontrolled asthma allergy require steroid No know hypersensitivity prior anaphylactic reaction murine proteins component study drug PRIOR CONCURRENT THERAPY : Biologic therapy : No prior rituximab No prior allogeneic autologous peripheral blood stem cell transplantation Concurrent filgrastim ( GCSF ) stem cell mobilization allow Chemotherapy : See Disease Characteristics No prior anthracyclines mitoxantrone No concurrent chemotherapy stem cell mobilization Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>